These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 21155632)
1. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. Retz W; Rösler M; Ose C; Scherag A; Alm B; Philipsen A; Fischer R; Ammer R; World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632 [TBL] [Abstract][Full Text] [Related]
2. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Rösler M; Fischer R; Ammer R; Ose C; Retz W Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529 [TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198 [TBL] [Abstract][Full Text] [Related]
4. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312 [TBL] [Abstract][Full Text] [Related]
5. Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder. López FA; Faraone SV; Newcorn JH; Doll HA; Rhoten S; Lewis HB; Khan TF; DeSousa NJ; Sallee FR; Incledon B J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):179-186. PubMed ID: 33797983 [No Abstract] [Full Text] [Related]
6. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder. Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study. Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989 [TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Buitelaar JK; Trott GE; Hofecker M; Waechter S; Berwaerts J; Dejonkheere J; Schäuble B Int J Neuropsychopharmacol; 2012 Feb; 15(1):1-13. PubMed ID: 21798108 [TBL] [Abstract][Full Text] [Related]
9. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate. Buitelaar JK; Casas M; Philipsen A; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; van Oene JC; Schäuble B Psychol Med; 2012 Jan; 42(1):195-204. PubMed ID: 21733214 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan. Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065 [TBL] [Abstract][Full Text] [Related]
11. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Fallu A; Richard C; Prinzo R; Binder C Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853 [TBL] [Abstract][Full Text] [Related]
14. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943 [TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder. Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903 [No Abstract] [Full Text] [Related]
16. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L; Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560 [TBL] [Abstract][Full Text] [Related]
17. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356 [No Abstract] [Full Text] [Related]
18. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Huss M; Ginsberg Y; Tvedten T; Arngrim T; Philipsen A; Carter K; Chen CW; Kumar V Adv Ther; 2014 Jan; 31(1):44-65. PubMed ID: 24371021 [TBL] [Abstract][Full Text] [Related]
19. Open-label dose optimization of methylphenidate modified release long acting (MPH-LA): a post hoc analysis of real-life titration from a 40-week randomized trial. Huss M; Ginsberg Y; Arngrim T; Philipsen A; Carter K; Chen CW; Gandhi P; Kumar V Clin Drug Investig; 2014 Sep; 34(9):639-49. PubMed ID: 25015027 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]